Sana Biotechnology Net Worth
Sana Biotechnology Net Worth Breakdown | SANA |
Sana Biotechnology Net Worth Analysis
Sana Biotechnology's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Sana Biotechnology's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Sana Biotechnology's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Sana Biotechnology's net worth analysis. One common approach is to calculate Sana Biotechnology's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Sana Biotechnology's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Sana Biotechnology's net worth. This approach calculates the present value of Sana Biotechnology's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Sana Biotechnology's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Sana Biotechnology's net worth. This involves comparing Sana Biotechnology's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Sana Biotechnology's net worth relative to its peers.
Enterprise Value |
|
To determine if Sana Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sana Biotechnology's net worth research are outlined below:
| Sana Biotechnology generated a negative expected return over the last 90 days | |
| Sana Biotechnology has high historical volatility and very poor performance | |
| Sana Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (283.25 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Sana Biotechnology currently holds about 484.8 M in cash with (253.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.57. | |
| Sana Biotechnology has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Williams Douglas E of 67083 shares of Sana Biotechnology subject to Rule 16b-3 |
Sana Biotechnology Quarterly Good Will |
|
Sana Biotechnology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sana Biotechnology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sana Biotechnology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Sana Biotechnology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sana Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sana Biotechnology backward and forwards among themselves. Sana Biotechnology's institutional investor refers to the entity that pools money to purchase Sana Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 2.9 M | Alphabet Inc | 2024-06-30 | 2.8 M | Baker Bros Advisors Lp | 2024-09-30 | 2.4 M | Integral Health Asset Management, Llc | 2024-09-30 | 1.8 M | Boxer Capital Llc | 2024-09-30 | 1.5 M | Northern Trust Corp | 2024-09-30 | 1.1 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.1 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1 M | Jpmorgan Chase & Co | 2024-06-30 | 951.6 K | Fmr Inc | 2024-09-30 | 31.6 M | Flagship Ventures Management, Inc. | 2024-06-30 | 25 M |
Follow Sana Biotechnology's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 582.73 M.Market Cap |
|
Project Sana Biotechnology's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.78) | (0.81) | |
| Return On Capital Employed | (0.65) | (0.69) | |
| Return On Assets | (0.50) | (0.53) | |
| Return On Equity | (0.99) | (0.94) |
When accessing Sana Biotechnology's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Sana Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sana Biotechnology's profitability and make more informed investment decisions.
Please note, the presentation of Sana Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sana Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sana Biotechnology's management manipulating its earnings.
Evaluate Sana Biotechnology's management efficiency
Sana Biotechnology has return on total asset (ROA) of (0.3115) % which means that it has lost $0.3115 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.929) %, meaning that it created substantial loss on money invested by shareholders. Sana Biotechnology's management efficiency ratios could be used to measure how well Sana Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.81. In addition to that, Return On Capital Employed is expected to decline to -0.69. At present, Sana Biotechnology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 361.6 M, whereas Non Currrent Assets Other are forecasted to decline to about 6.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.48 | 1.55 | |
| Tangible Book Value Per Share | 0.45 | 0.47 | |
| Enterprise Value Over EBITDA | (3.03) | (3.18) | |
| Price Book Value Ratio | 2.76 | 2.90 | |
| Enterprise Value Multiple | (3.03) | (3.18) | |
| Price Fair Value | 2.76 | 2.90 | |
| Enterprise Value | 7.2 B | 7.1 B |
Leadership effectiveness at Sana Biotechnology is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Return On Equity (0.93) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sana Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sana Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sana Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sana Biotechnology Corporate Filings
| 21st of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 22nd of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Sana Biotechnology Earnings per Share Projection vs Actual
Sana Biotechnology Corporate Management
| Sunil MD | Head VP | Profile | |
| Christian MBA | Executive Officer | Profile | |
| Shanna Peek | Sr Operations | Profile | |
| Richard Mulligan | Executive Research | Profile | |
| Sonja MD | Senior Platform | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sana Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Return On Assets (0.31) | Return On Equity (0.93) |
The market value of Sana Biotechnology is measured differently than its book value, which is the value of Sana that is recorded on the company's balance sheet. Investors also form their own opinion of Sana Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Sana Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sana Biotechnology's market value can be influenced by many factors that don't directly affect Sana Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sana Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sana Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.